5 New Monosan Multidrug Resistance Antibodies

Chemotherapy has many advances in the treatment of disseminated tumors and although it is quite effective in treating certain cancers, other types of cancer respond to chemotherapy either poorly or partially. Failure of chemotherapeutic regimens may be due to different factors, including the inability of the drug to reach the tumor site. Tumor cell that are insensitive to anticancer drugs frequently have a multidrug resistance MDR phenotype. The MRP gene product, Multidrug Resistance-associated protein has been shown to confer a similar resistance phenotype. The understanding of these mechanisms is fundamental to developing strategies aimed to prevent or circumvent resistance, thus improving the results of chemotherapy.

Monosan have released the following 5 antisera, complimenting the existing extensive range of Multidrug Resistant antisera.
 

Cat. no. MON9123 Moab x MRP5 (ABCC5), clone M5I-10
Cat. no. MON9124 Moab x MRP7 (ABCC10), clone M7I-3
Cat. no. MON9120 Moab x MRP8 (ABCC11), clone M8I-74
Cat. no. MON9121 Moab x MRP9 (ABCC12), clone M9I-38
Cat. no. MON9122 Moab x MRP9 (ABCC12), clone M9II-3
 

Size: 1 ml vials (>>200 tests) containing antibody in serumfree culture supernatant, with 0.7% BSA and 0.1% sodium azide.
Concentration: 250 μg immunoglobulin/ml (by ELISA)
Use: The antibody is useful for immunocytochemistry (acetone fixed cytospin preparations), immunohistochemisty on frozen sections and Western blotting.